Brief: Panbela Opens Enrollment In UK And Germany For Aspire Trial In Pancreatic Cancer
24/07/2023 14:14
July 24 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA OPENS ENROLLMENT IN UK AND GERMANY FOR ASPIRE
TRIAL IN
PANCREATIC CANCER, ALL COUNTRIES/REGIONS IN THE ASPIRE TRIAL ARE
NOW OPEN AND ACTIVELY ENROLLING
* PANBELA THERAPEUTICS INC - FOCUSED ON HAVING ALL SITES
OPEN FOR
ENROLLMENT WITHIN NEXT COUPLE MONTHS, THEN TOWARDS INTERIM DATA
ANALYSIS IN EARLY 2024
Source text for Eikon: ID:nGNX5wl7ZD
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants